Clinical Trial Results:
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Schizophrenia
“ASPIRE US” (Aripiprazole Intramuscular Depot Program in Schizophrenia)
Summary
|
|
EudraCT number |
2008-002675-27 |
Trial protocol |
BG SK |
Global completion date |
08 Feb 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1 |
This version publication date |
05 Nov 2016
|
First version publication date |
05 Nov 2016
|
Other versions |
v2 |
Summary report(s) |
31-07-246 CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.